| Name | Title | Contact Details |
|---|---|---|
Heather Gervais |
Chief Technology Officer | Profile |
St. Joseph of the Pines Health System is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. St. Joseph of the Pines Health System is based in Newark, NJ. You can find more information on St. Joseph of the Pines Health System at www.sjp.org
CNR Health Care Network is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The HCA Physician Services Group, a part of the HCA family, is focused on implementing innovative, value-added solutions that help our physicians deliver high quality, cost effective healthcare and support HCA`s commitment to the care and improvement of human life. As the physician solution for HCA, the Physician Services Group makes it easier for physicians to practice medicine by reducing the burdens of managing an independent practice and infusing the best clinical and operational standards in every office. The Physician Services Group is always looking for great people who are passionate about caring for human life. We are looking for experienced health care executives, skilled operators, area and market managers, practice managers, accountants, coders, business analysts, charge entry specialists, medical assistants and all around leaders ready for their next great opportunity.
We`ve pioneered digital behavioral medicine: a new approach to tackling the growing epidemic of type 2 diabetes, heart disease, and obesity. Our online programs combine world-class science, technology, and design to inspire and enable people everywhere to live free of chronic disease. Named one of Fast Company`s “50 Most Innovative Companies in the World,” our team includes passionate and talented individuals from Google, IDEO, Harvard, Stanford, and Columbia. Our approach has been embraced by major employers across the country, including Costco and Iron Mountain, as well as leading health plans, such as Kaiser Permanente and Humana.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.